Edwards Lifesciences Corp (EW) : Peak6 Investments scooped up 14,829 additional shares in Edwards Lifesciences Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 87,023 shares of Edwards Lifesciences Corp which is valued at $9 Million.Edwards Lifesciences Corp makes up approximately 0.72% of Peak6 Investments’s portfolio.
Other Hedge Funds, Including , Cantab Capital Partners Llp boosted its stake in EW in the latest quarter, The investment management firm added 4,300 additional shares and now holds a total of 14,709 shares of Edwards Lifesciences Corp which is valued at $1.5 Million. Edwards Lifesciences Corp makes up approx 0.41% of Cantab Capital Partners Llp’s portfolio. Massachusetts Financial Services Co sold out all of its stake in EW during the most recent quarter. The investment firm sold 12,986 shares of EW which is valued $1.3 Million.Penserra Capital Management reduced its stake in EW by selling 2,743 shares or 33.31% in the most recent quarter. The Hedge Fund company now holds 5,491 shares of EW which is valued at $565,518. Edwards Lifesciences Corp makes up approx 0.08% of Penserra Capital Management’s portfolio.Lmr Partners Llp boosted its stake in EW in the latest quarter, The investment management firm added 1,622 additional shares and now holds a total of 19,967 shares of Edwards Lifesciences Corp which is valued at $2.1 Million. Edwards Lifesciences Corp makes up approx 0.32% of Lmr Partners Llp’s portfolio. Manchester Capital Management sold out all of its stake in EW during the most recent quarter. The investment firm sold 180 shares of EW which is valued $19,033.
Edwards Lifesciences Corp closed down -1.58 points or -1.56% at $99.91 with 15,25,779 shares getting traded on Wednesday. Post opening the session at $101.79, the shares hit an intraday low of $99.69 and an intraday high of $101.96 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Canaccord Genuity on May 23, 2016 to “Buy”, Firm has raised the Price Target to $ 132 from a previous price target of $123 .Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $110 .Company shares were Reiterated by Canaccord Genuity on Apr 27, 2016 to “Buy”, Firm has raised the Price Target to $ 123 from a previous price target of $113 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.